Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ELVN-001 in Japanese Participants With Chronic Myeloid Leukemia
jRCT2011240057Phase 1Recruiting
- Sponsor
- Enliven Therapeutics
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of relcobatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Enliven Therapeutics. Primary endpoints: Incidence of dose-limiting toxicities (DLTs) and Incidence of adverse events (AEs), laboratory abnormalities, and electrocardiogram (ECG) abnormalities. Started Dec 2024; status: recruiting.
02
Drugs
relcobatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT2011240057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240057.